Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 8/20 | 0.45 |
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 7/20 | 0.45 |
| ▸ | CA9 | Q16790 | 7/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17190641 | 0.93 | TDP1 (0.49) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL21275782 | 0.93 | TDP1 (0.49) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL10030615 | 0.89 | TDP1 (0.61) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL2523550 | 0.88 | TDP1 (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| Hydrochloric Acid SCHEMBL2523548 | 0.86 | TDP1 (0.53) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL7097924 | 0.84 | TDP1 (0.65) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL25953755 | 0.84 | TDP1 (0.47) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1557954 | 0.84 | TDP1 (0.56) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL11988220 | 0.83 | TDP1 (0.58) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3341020 | 0.83 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10314922-B2 | Trimaleimide linkers and uses thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2019-06-11 | — | — | US | disclosed |
| US-20180147295-A1 | Trimaleimide Linkers and Uses Thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2018-05-31 | — | — | US | disclosed |
| EP-2887963-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016192528-A1 | Trimaleimide Linkers and Uses Thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2016-12-08 | — | — | WO | disclosed |
| US-20150299131-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2014029984-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147295-A1 | Trimaleimide Linkers and Uses Thereof | TXLNA, TRIM59, NAALAD2 | TDP1 1463/4885MEN1 1621/4885GAA 1658/4885 |
| US-20150299131-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | TDP1 4348/4885MEN1 4780/4885GAA 746/4885 |
| US-10314922-B2 | Trimaleimide linkers and uses thereof | TXLNA, NAALAD2, TTL | TDP1 1200/4885MEN1 1472/4885GAA 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.